GSK says melanoma combination meets main goal
LONDON Jan 24 (Reuters) - GlaxoSmithKline said on Friday the first of its phase three studies into the combination of Tafinlar and Mekinist to treat melanoma, the deadliest form of skin cancer, had met its main goal.
The results, along with further data expected from the study, will increase the body of evidence on the safety and efficiacy of the combination, the British company said.
The combined use of Tafinlar, also known as dabrafenib, and Mekinist, or trametinib, was given the green light from the Food and Drug Administration (FDA) in the U.S. earlier this month.
- Missing jet may have strayed toward Andaman Sea: Malaysian air force |
- NYC buildings explosion kills two, more missing
- EU moves towards travel bans, asset freezes for Russians |
- Malaysia military source says missing jet veered to west |
- Exclusive: EU approves framework for asset freezes, travel bans on Russia